RT Journal Article
SR Electronic
T1 Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.30.22275753
DO 10.1101/2022.05.30.22275753
A1 Xiaoqiang Liu
A1 Yuhua Li
A1 Zhongfang Wang
A1 Shouchun Cao
A1 Weijin Huang
A1 Lin Yuan
A1 Yi-Jiao Huang
A1 Yan Zheng
A1 Jingjing Chen
A1 Bo Ying
A1 Zuoyun Xiang
A1 Jin Shi
A1 Jincun Zhao
A1 Zhen Huang
A1 Cheng-Feng Qin
YR 2022
UL http://medrxiv.org/content/early/2022/05/31/2022.05.30.22275753.abstract
AB Homologous and heterologous booster with COVID-19 mRNA vaccines represent the most effective strategy to prevent the ongoing Omicron pandemic. The additional protection from these prototype SARS-CoV-2 S-targeting vaccine was attributed to the increased RBD-specific memory B cells with expanded potency and breadth. Herein, we show the safety and immunogenicity of heterologous boosting with the RBD-targeting mRNA vaccine AWcorna (also term ARCoV) in Chinese adults who have received two doses inactivated vaccine. The superiority over inactivated vaccine in neutralization antibodies, as well as the safety profile, support the use of AWcorna as heterologous booster in China.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2100053701Funding StatementThis work was supported in part by grant from the National Key Research and Development Program of China (2021YFC2302400) and the National Science Foundation of China (82151222). C.-F.Q. was supported by the National Science Fund for Distinguished Young Scholars (81925025), the Innovative Research Group (81621005) from the National Science Foundation of China and the Innovation Fund for Medical Sciences (2019-I2M-5-049) from the Chinese Academy of Medical Science.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Research Ethics Committee of the Center for Disease Control and Prevention of Yunnan province gave ethical approve for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.